HealthEquity, Inc. (NASDAQ:HQY) Director Evelyn S. Dilsaver Sells 32,500 Shares of Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Evelyn S. Dilsaver sold 32,500 shares of the company’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total value of $2,576,925.00. Following the completion of the sale, the director now owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $81.63 on Friday. HealthEquity, Inc. has a fifty-two week low of $48.86 and a fifty-two week high of $84.49. The business has a 50 day moving average price of $79.90 and a two-hundred day moving average price of $73.31. The company has a quick ratio of 4.93, a current ratio of 4.76 and a debt-to-equity ratio of 0.43. The firm has a market cap of $7.00 billion, a PE ratio of 127.55, a price-to-earnings-growth ratio of 1.34 and a beta of 0.53.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HQY. Barclays increased their target price on HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. BTIG Research upped their price target on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. Royal Bank of Canada upped their price target on HealthEquity from $90.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 20th. Wells Fargo & Company upped their price target on HealthEquity from $89.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 6th. Finally, Bank of America upped their price target on HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, HealthEquity currently has an average rating of “Moderate Buy” and a consensus target price of $92.55.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in HealthEquity by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 8,619,499 shares of the company’s stock worth $571,473,000 after buying an additional 104,084 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in HealthEquity by 24.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,129,634 shares of the company’s stock worth $74,895,000 after buying an additional 223,428 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in HealthEquity by 6.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 48,019 shares of the company’s stock worth $3,184,000 after buying an additional 2,712 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of HealthEquity in the 4th quarter worth approximately $1,475,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of HealthEquity by 14.3% in the 4th quarter. Public Employees Retirement System of Ohio now owns 102,196 shares of the company’s stock worth $6,776,000 after purchasing an additional 12,765 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.